Benzinga | Apr 12, 2021 05:43PM EDT

Pulmatrix Issues Press Release Correcting Info On Phase 2 Proof-Of-Concept Efficacy Study For Treatment Of AECOPD, Says Study Will Not Commence Until 2022

Pulmatrix, Inc. (NASDAQ:PULM), is re-issuing this press release solely to correct inadvertent typographical errors under the heading "Updated PUR1800 Program Guidance" which incorrectly noted that Pulmatrix plans to initiate a PUR1800 Phase 2 proof-of-concept efficacy study for the treatment of AECOPD in 2021. This study is not expected to commence until 2022 All other data and disclosure remain unchanged.